BioPharma Dealmakers A supplement to Nature Biotechnology and Nature Reviews Drug Discovery
This issue covers the partnering strategies of the industry's movers and shakers, the deals that are shaping our industry, the best emerging biotech and academic innovators, and the contract services that support them.
Drug companies look to biomarkers to salvage cancer target doi:10.1038/nm0912-1312a Drugs that target insulin-like growth factor receptors have produced mixed results. Now, some companies are exploring biomarker strategies, and new combinations, to try to achieve success. Full Text
Stop-work order creates uncertainty for Ebola drug research doi:10.1038/nm0912-1312b Concern is voiced at the pause in US Department of Defense-funded research into new drugs for Ebola. Full Text
Exon-skipping drug pulls ahead in muscular dystrophy field doi:10.1038/nm0912-1314 Therapies for Duchenne muscular dystrophy that are tailored to correct the mutations in the dystrophin-encoding gene that cause the disorder are moving into late-stage development. Full Text
Drug pipeline is flush with new options for chronic constipation doi:10.1038/nm0912-1308 A positive regulatory decision on linaclotide in the next month could provide a shift in the market for irritable bowel syndrome. Full Text
Dissociating the effects of A2A agonism doi:10.1038/scibx.2012.887 Researchers in Germany have dissociated the anti-inflammatory effects of adenosine A2A receptor agonists from their hemodynamic effects and are determining a specific inflammation-related indication to pursue with their lead molecule. Full Text
The pharmaceutical market for obesity therapies doi:10.1038/nrd3730 In the wake of the recent approvals of the first new obesity therapies in more than a decade, Wong and colleagues analyse their market prospects as well as the late-stage pipeline. Full Text
Cancer: Passenger deletions create cancer-specific Achilles heel doi:10.1038/nrd3826 Cancer cells tend to shed tumour suppressor genes — and often delete neighbouring genes in the process. New research shows that genes deleted in cells that neighbour cancer cells create cancer cell-specific vulnerabilities that can be targeted by new anticancer strategies. Full Text
Structure-based drug design: Opening the door to an epigenetic target doi:10.1038/nrd3827 A structure-guided approach has been used to identify the first specific small-molecule inhibitor of a jumonji histone demethylase. Full Text
Ischaemic disorders: Nanotherapeutic delivers clot-busting drug doi:10.1038/nrd3828 Shear-activated nanotherapeutics can deliver thrombolytic drugs to the site of vascular occlusion, enabling rapid clot dissolution and an increase in survival in mouse models. Full Text
Autophagy modulation as a potential therapeutic target for diverse diseases doi:10.1038/nrd3802 This article provides an overview of the mechanisms and regulation of autophagy, the role of this pathway in disease and strategies for therapeutic modulation. Full Text
Limitations in anti-obesity drug development: the critical role of hunger-promoting neurons doi:10.1038/nrd3739 Emerging knowledge on the role of the hypothalamus may facilitate the discovery of new agents that are more effective than current anti-obesity drugs, and have an acceptable benefit–risk profile. Full Text
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis doi:10.1038/nchembio.1060 A small-molecule activator specific for PKM2 binds to a site distinct from the endogenous activator fructose-1,6-bisphosphate, promoting tetramerization and constitutive activation of PKM2, to inhibit xenograft tumor growth in mice. Full Text
EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans doi:10.1038/nm.2901 Genetic or pharmacological inhibition of Epha4 is protective in rodent and zebrafish models of amyotrophic lateral sclerosis. In two patients, mutations in Epha4 are associated with longer survival, suggesting Epha4 may be targeted therapeutically. Full Text
Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text
SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why.
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant)
Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston
Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.
No comments:
Post a Comment